Phase II study of high-dose somatostatin analogue in patients either previously treated or untreated who have extensive-stage small cell lung cancer

Robert F. Marschke, Joseph P. Grill, Jeff A. Sloan, Donald B. Wender, Ralph Levitt, James A. Mailliard, James B. Gerstner, Chirantan Ghosh, Roscoe F. Morton, James R. Jett

Research output: Contribution to journalArticle

20 Scopus citations

Abstract

The authors conducted a phase II study of somatostatin analogue in 18 patients with extensive stage small cell lung cancer (four with previous treatment, 14 without previous treatment). Patients received 2,000 mg subcutaneously thrice daily. They were required to have an Eastern Cooperative Oncology Group performance score of 0-2 and acceptable pretreatment biochemical parameters. No patient responded to treatment. The median time to progression was 44 days. The median survival was 106 days. Toxicity related to treatment consisted of mild diarrhea and anorexia. Somatostatin analogue is not active as a single agent in the treatment of extensive-stage small cell lung cancer.

Original languageEnglish (US)
Pages (from-to)15-17
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume22
Issue number1
DOIs
StatePublished - Feb 1 1999

Keywords

  • Analogue
  • Somatostatin
  • Stage

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II study of high-dose somatostatin analogue in patients either previously treated or untreated who have extensive-stage small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this